GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004338811 | Stomach | CAG with IM | positive regulation of DNA binding | 10/1050 | 56/18723 | 9.93e-04 | 1.27e-02 | 10 |
GO:005116811 | Stomach | CAG with IM | nuclear export | 19/1050 | 154/18723 | 1.02e-03 | 1.29e-02 | 19 |
GO:000641711 | Stomach | CAG with IM | regulation of translation | 43/1050 | 468/18723 | 1.03e-03 | 1.29e-02 | 43 |
GO:00466831 | Stomach | CAG with IM | response to organophosphorus | 17/1050 | 131/18723 | 1.05e-03 | 1.30e-02 | 17 |
GO:004343411 | Stomach | CAG with IM | response to peptide hormone | 39/1050 | 414/18723 | 1.09e-03 | 1.33e-02 | 39 |
GO:190290411 | Stomach | CAG with IM | negative regulation of supramolecular fiber organization | 20/1050 | 167/18723 | 1.11e-03 | 1.36e-02 | 20 |
GO:003497611 | Stomach | CAG with IM | response to endoplasmic reticulum stress | 27/1050 | 256/18723 | 1.22e-03 | 1.48e-02 | 27 |
GO:200005911 | Stomach | CAG with IM | negative regulation of ubiquitin-dependent protein catabolic process | 9/1050 | 48/18723 | 1.23e-03 | 1.48e-02 | 9 |
GO:20012381 | Stomach | CAG with IM | positive regulation of extrinsic apoptotic signaling pathway | 9/1050 | 48/18723 | 1.23e-03 | 1.48e-02 | 9 |
GO:00086301 | Stomach | CAG with IM | intrinsic apoptotic signaling pathway in response to DNA damage | 14/1050 | 99/18723 | 1.23e-03 | 1.48e-02 | 14 |
GO:00326401 | Stomach | CAG with IM | tumor necrosis factor production | 21/1050 | 181/18723 | 1.27e-03 | 1.52e-02 | 21 |
GO:00326801 | Stomach | CAG with IM | regulation of tumor necrosis factor production | 21/1050 | 181/18723 | 1.27e-03 | 1.52e-02 | 21 |
GO:004315411 | Stomach | CAG with IM | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 12/1050 | 78/18723 | 1.28e-03 | 1.53e-02 | 12 |
GO:003158911 | Stomach | CAG with IM | cell-substrate adhesion | 35/1050 | 363/18723 | 1.29e-03 | 1.53e-02 | 35 |
GO:200037711 | Stomach | CAG with IM | regulation of reactive oxygen species metabolic process | 19/1050 | 157/18723 | 1.29e-03 | 1.53e-02 | 19 |
GO:00427421 | Stomach | CAG with IM | defense response to bacterium | 34/1050 | 350/18723 | 1.32e-03 | 1.56e-02 | 34 |
GO:00104986 | Stomach | CAG with IM | proteasomal protein catabolic process | 44/1050 | 490/18723 | 1.43e-03 | 1.64e-02 | 44 |
GO:00972841 | Stomach | CAG with IM | hepatocyte apoptotic process | 5/1050 | 16/18723 | 1.43e-03 | 1.64e-02 | 5 |
GO:200126711 | Stomach | CAG with IM | regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 5/1050 | 16/18723 | 1.43e-03 | 1.64e-02 | 5 |
GO:003086611 | Stomach | CAG with IM | cortical actin cytoskeleton organization | 8/1050 | 40/18723 | 1.47e-03 | 1.67e-02 | 8 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |